HCPCS Level II code J1447 identifies tbo-filgrastim, a granulocyte colony-stimulating factor, dosed per microgram for injection. This code is used to bill the supply of the biologic when administered to reduce the duration of neutropenia or support hematopoietic recovery. Nationally, biologic supportive therapies such as tbo-filgrastim are important for oncology care pathways and post-transplant management given their role in reducing infection risk and supporting chemotherapy delivery.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J1447 is defined, the clinical context for its use, and what to expect in claims for outpatient injectable biologic services. Content covers national benchmarks where available, payer coverage considerations, and recent policy updates relevant to injectable hematopoietic growth factors. The publication also outlines coding considerations and common billing practices for service lines that deliver injectable biologics in ambulatory and hospital outpatient settings.

Data not available in the input for specific reimbursement rates, associated taxonomies, and ICD-10 linkage; those fields are noted as unavailable where applicable.